India’s biggest biopharmaceutical company, Biocon Ltd, is building a plant to produce insulin for diabetics in Malaysia.
It started the plant’s construction in Johor in mid-2012, pumping 160 million USD into the venture’s first phase, said President of Marketing at Biocon Ravi Limaye.
The company will invest an additional 40 million USD into phase 2 of the plant, depending on the matching capacity requirements, Ravi said.
The state-of-the-art manufacturing facility in Johor will boost Biocon’s producing capacity, making it the world’s third largest insulin supplier.
Chief Executive Officer of CCM Leonard Ariff Abdul Shatar believed that cooperating with Biocon will bring value to the country’s 21 million USD insulin market.
Biocon Ltd is cooperating with Chemical Company of Malaysia Bhd (CCM) to sell Insugen and Insupen in the country in 2015.
According the Malaysian Ministry of Health, around 3 million Malaysian adults are diabetics.-VNA
It started the plant’s construction in Johor in mid-2012, pumping 160 million USD into the venture’s first phase, said President of Marketing at Biocon Ravi Limaye.
The company will invest an additional 40 million USD into phase 2 of the plant, depending on the matching capacity requirements, Ravi said.
The state-of-the-art manufacturing facility in Johor will boost Biocon’s producing capacity, making it the world’s third largest insulin supplier.
Chief Executive Officer of CCM Leonard Ariff Abdul Shatar believed that cooperating with Biocon will bring value to the country’s 21 million USD insulin market.
Biocon Ltd is cooperating with Chemical Company of Malaysia Bhd (CCM) to sell Insugen and Insupen in the country in 2015.
According the Malaysian Ministry of Health, around 3 million Malaysian adults are diabetics.-VNA
